Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases
Filipa Viegas,Tiago Ferreira,Cláudia Campos
DOI: https://doi.org/10.2147/NDT.S343747
IF: 2.989
2022-06-09
Neuropsychiatric Disease and Treatment
Abstract:Filipa Viegas, Tiago Ferreira, Cláudia Campos Mental Health Department Hospital Prof. Dr. Fernando Fonseca, Amadora, Portugal Correspondence: Filipa Viegas, Mental Health Department Hospital Prof. Dr. Fernando Fonseca, IC-19, Amadora, 2720-276, Portugal, Tel +351 91 744 87 81, Email Introduction: Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors, partial agonism at 5-HT1A receptors, and low affinity to other receptors (including noradrenergic, histaminergic, and cholinergic). It has demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia with a safe side effect and metabolic profile. Methods: Here, we describe one clinical case of a patient that benefited from an add-on of cariprazine to a regimen of clozapine; and two clinical cases of patients that benefited from the switch from clozapine and paliperidone long-acting injectable to cariprazine. Results and Discussion: Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments. However, further studies are needed to consubstantiate those findings. Keywords: cariprazine, clozapine, paliperidone, schizophrenia, negative symptoms Schizophrenia is a chronic and disabling disease, affecting mental and social functions. 1,2 Typically, the symptoms can be classified in the following domains: positive symptoms (such as delusions and hallucinations), negative symptoms (alogia, anhedonia, asociality, avolition, and blunted affect), and cognitive symptoms (such as impaired learning, thinking, memorizing, among others). 1,3 Patients with schizophrenia vary broadly with regard to the symptoms and these may change with time, with different symptoms becoming the predominant symptoms at different times. 4 Antipsychotics are a central part of schizophrenia management, although complete remission or recovery of symptoms is relatively rare and some patients have a resistant disease (treatment-refractory schizophrenia is defined as failure of two attempts of adequate antipsychotic medical treatment). 1–3 Despite the greater efficacy of clozapine over other antipsychotics in the management of resistant schizophrenia, this drug has a high propensity for weight gain and general metabolic dysregulation, and a noteworthy number of patients still do not attain an adequate response. 2,5 Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia, with D3/D2 partial agonist properties and preferential binding to D3 receptors, and has the potential to be of additional value, because of its exceptional receptor profile and tolerability. 1,2,6 In addition to partial agonist activity at D3 and D2 receptors, it is also an antagonist at the serotonin 5-HT2A and 5-HT2B receptors, a partial agonist at 5-HT1A receptors, and has a low affinity at other receptors, including noradrenergic, histaminergic, and cholinergic receptors. 1 Studies suggest that cariprazine may be of particular interest regarding the treatment of negative symptoms, and some reports additionally suggest its usefulness in treatment-refractory schizophrenia. It is also a useful alternative to patients with serious metabolic side effects from antipsychotic medication. 1,2,6 Here, we report a case of a patient with clozapine-resistant schizophrenia who responded to cariprazine combination, a case of a clozapine-resistant schizophrenia who responded to cariprazine monotherapy, and a case of a patient with serious metabolic side effects related to paliperidone long acting injectable (LAI) that benefited from a switch to cariprazine. Written informed consent for publication of patients' details was obtained. He is a 29-year-old, unemployed and unmarried man, with a long history of schizophrenia. At the age of 22, he was admitted to a psychiatric ward with a one-year history of persecutory delusional ideas, running commentary hallucinations, and behavioral changes with marked agitation. At the psychiatry ward, risperidone was tried for up to 8 mg/day, but clinical remission was not seen, so a switch to olanzapine was made. He was discharged with olanzapine 30 mg daily and flurazepam 30 mg but maintained hallucinations, abulia, hypersomnia and psychomotor retardation with significant compromise in functionality. He did not adhere to the proposed socio-occupational projects, preserving hallucinatory activity and ne -Abstract Truncated-
psychiatry,clinical neurology